Combretastatin A4 - CAS 117048-59-6
Catalog number:
117048-59-6
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C18H20O5
Molecular Weight:
316.35
COA:
Inquire
Targets:
Microtubule/Tubulin
Description:
Combretastatin A4, under the IUPAC name 2-methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenol, inhibits tubulin polymerization (IC50= 2.2 μM). It has demonstrable antineoplastic activity (inhibit IMR32 (neuroblastoma): IC50= 2.16nM, Hs746T (gastric carcinoma) IC50=5.20nM, CFPAC-1 (pancreatic carcinoma)IC50=3.46nM, and MCF-7 (breast cancer)IC50=18.47nM
Publictions citing BOC Sciences Products
  • >> More
Brife Description:
Inhibits tubulin polymerization (IC50= 2.2 μM)
Appearance:
Solid powder
Synonyms:
2-methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenol; 1-(3,4,5-trimethoxyphenyl)-2-(3'-hydroxy-4'-methoxyphenyl)ethene; D-64131; 74588-78-6; (5-METHOXY-1H-INDOL-2-YL)PHENYLMETHANONE; CHEMBL140220; C16H13NO2; (5-methoxy-1H-indol-2-yl)-phenylmethanone; (5-Methoxy-1H-indol-2-yl)(phenyl)methanone; (5-Methoxy-1H-indol-2-yl)-phenyl-methanone; NCGC00025243-01; Tocris-1643; AC1N0QCR; 2-Benzoyl-5-methoxyindole; SCHEMBL5828518; CTK8F8930; DTXSID30397970; ICMIJSRDISNKOC-UHFFFAOYSA-N; HMS3268K07; ZINC2526466; 3570AH; BDBM50107658; AKOS022507157; CS-1008; 2-BENZOYL-5-METHOXY-1H-INDOLE; NCGC00025243-02; AN-25376; HE053371; HE187776; HY-15482; LS-83224; QC-11710; AB0165802; KB-208742; D64131; W-5310; BRD-K26997899-001-01-4; D-64131|(5-Methoxy-1H-indol-2-yl)phenylmethanone
Solubility:
Soluble to 100 mM in ethanol and to 100 mM in DMSO
Storage:
Store in a cool and dry place and at 0 - 4℃ for short term (days to weeks) or -53℃ for long term (months to years).
MSDS:
Inquire
Melting Point:
84.5-85.5ºC
Density:
1.184 g/cm3
InChIKey:
HVXBOLULGPECHP-WAYWQWQTSA-N
InChI:
1S/C18H20O5/c1-20-15-8-7-12(9-14(15)19)5-6-13-10-16(21-2)18(23-4)17(11-13)22-3/h5-11,19H,1-4H3/b6-5-
Canonical SMILES:
COC1=C(C=C(C=C1)C=CC2=CC(=C(C(=C2)OC)OC)OC)O
1.Combretastatins: more than just vascular targeting agents?
Greene LM1, Meegan MJ2, Zisterer DM2. J Pharmacol Exp Ther. 2015 Nov;355(2):212-27. doi: 10.1124/jpet.115.226225. Epub 2015 Sep 9.
Several prodrugs of the naturally occurring combretastatins have undergone extensive clinical evaluation as vascular targeting agents (VTAs). Their increased selectivity toward endothelial cells together with their innate ability to rapidly induce vascular shutdown and inhibit tumor growth at doses up to 10-fold less than the maximum tolerated dose led to the clinical evaluation of combretastatins as VTAs. Tubulin is well established as the molecular target of the combretastatins and the vast majority of its synthetic derivatives. Furthermore, tubulin is a highly validated molecular target of many direct anticancer agents routinely used as front-line chemotherapeutics. The unique vascular targeting properties of the combretastatins have somewhat overshadowed their development as direct anticancer agents and the delineation of the various cell death pathways and anticancer properties associated with such chemotherapeutics. Moreover, the ongoing clinical trial of OXi4503 (combretastatin-A1 diphosphate) together with preliminary preclinical evaluation for the treatment of refractory acute myelogenous leukemia has successfully highlighted both the indirect and direct anticancer properties of combretastatins.
2.Stepwise pH-responsive nanoparticles containing charge-reversible pullulan-based shells and poly(β-amino ester)/poly(lactic-co-glycolic acid) cores as carriers of anticancer drugs for combination therapy on hepatocellular carcinoma.
Zhang C1, An T1, Wang D1, Wan G1, Zhang M2, Wang H1, Zhang S1, Li R1, Yang X1, Wang Y3. J Control Release. 2016 Mar 28;226:193-204. doi: 10.1016/j.jconrel.2016.02.030. Epub 2016 Feb 16.
Stepwise pH-responsive nanoparticle system containing charge reversible pullulan-based (CAPL) shell and poly(β-amino ester) (PBAE)/poly(lactic-co-glycolic acid) (PLAG) core is designed to be used as carriers of paclitaxel (PTX) and combretastatin A4 (CA4) for combining antiangiogenesis and chemotherapy to treat hepatocellular carcinoma (HCC). CAPL-coated PBAE/PLGA (CAPL/PBAE/PLGA) nanoparticles displayed step-by-step responses to weakly acidic tumor microenvironment (pH ≈6.5) and endo/lysosome (pH ≈5.5) respectively through the cleavage of β-carboxylic amide bond in CAPL and the "proton-sponge" effect of PBAE, thus realized the efficient and orderly releases of CA4 and PTX. In human HCC HepG2 cells and human umbilical vein endothelial cells, CAPL/PBAE/PLGA nanoparticles significantly enhanced synergistic effects of PTX and CA4 on cell proliferation and cell migration. In HepG2 tumor-bearing mice, CAPL/PBAE/PLGA nanoparticles showed excellent tumor-targeting capability and remarkably increased inhibitory effects of PTX and CA4 on tumor growth and angiogenesis.
3.Combretastatin A-4 Conjugated Antiangiogenic Micellar Drug Delivery Systems Using Dendron-Polymer Conjugates.
Sumer Bolu B1, Manavoglu Gecici E1, Sanyal R1,2. Mol Pharm. 2016 Apr 14. [Epub ahead of print]
Employment of polymeric nanomaterials in cancer therapeutics is actively pursued since they often enable drug administration with increased efficacy along with reduced toxic side effects. In this study, drug conjugated micellar constructs are fabricated using triblock dendron-linear polymer conjugates where a hydrophilic linear polyethylene glycol (PEG) chain is flanked by well-defined hydrophobic biodegradable polyester dendrons bearing an antiangiogenic drug, combretastatin-A4 (CA4). Variation in dendron generation is utilized to obtain a library of micellar constructs with varying sizes and drug loadings. In particular, a family of drug appended dendron-polymer conjugates based on polyester dendrons of generations ranging from G1 to G3 and 10 kDa linear PEG were obtained using [3 + 2] Huisgen type "click" chemistry. The final constructs benefit from PEG's hydrophilicity and antibiofouling character, as well as biodegradable nature of the hydrophobic polyester dendrons.
4.Synthesis and Evaluation of 131I-Skyrin as a Necrosis Avid Agent for Potential Targeted Radionuclide Therapy of Solid Tumors.
Wang C1,2, Jin Q2, Yang S2, Zhang D2, Wang Q2,3, Li J1,2, Song S4, Sun Z5, Ni Y6, Zhang J2, Yin Z1. Mol Pharm. 2015 Dec 17. [Epub ahead of print]
An innovative anticancer approach targeted to necrotic tissues, which serves as a noncancerous and generic anchor, may present a breakthrough. Necrosis avid agents with a flat conjugate aromatic structure selectively accumulate in necrotic tissues, but they easily form aggregates that undesirably distribute to normal tissues. In this study, skyrin, a dianthraquinone compound with smaller and distorted π-cores and thus decreased aggregates as compared with hypericin (Hyp), was designed to target necrosis for tumor therapy. Aggregation studies of skyrin by UV/vis spectroscopy showed a smaller self-association constant with skyrin than with Hyp. Skyrin was labeled by iodine-131 with a radiochemical purity of 98% and exhibited good stability in rat serum for 72 h. In vitro cell uptake studies showed significant difference in the uptake of 131I-skyrin by necrotic cells compared to normal cells (P < 0.05). Compared in rats with liver and muscle necrosis, radiobiodistribution, whole-body autoradiography, and SPECT/CT studies revealed higher accumulation of 131I-skyrin in necrotic liver and muscle (p < 0.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Microtubule/Tubulin Products


PBOX-15
(CAS: 354759-10-7)

PBOX-15 is a novel microtubule inhibitor, which induces apoptosis, upregulates death receptors, and potentiates TRAIL-mediated apoptosis in multiple myeloma cel...

ALB 109564(a) dihydrochloride
(CAS: 1300114-12-8)

ALB 109564(a) is a Tubulin inhibitor as a semi-synthetic derivative of the vinka alkaloid originated by AMRI. It can bind to tubulin monomers and inhibit microt...

CAS 82855-09-2 Combretastatin

Combretastatin
(CAS: 82855-09-2)

Combretastatin is a dihydrostilbenoid that found in Combretum caffrum. Members of the combretastatin family shows varying ability to cause vascular disruption i...

CAS 917111-49-0 Lexibulin dihydrochloride

Lexibulin dihydrochloride
(CAS: 917111-49-0)

Lexibulin dihydrochloride is an orally bioavailable small-molecule with tubulin-inhibiting, vascular-disrupting, and potential antineoplastic activities. It inh...

CAS 1201898-17-0 Vinflunine Tartrate

Vinflunine Tartrate
(CAS: 1201898-17-0)

Vinflunine induces apoptosis in neuroblastoma SK-N-SH cells through a postmitotic G1 arrest and a mitochondrial pathway in a concentration-dependent manner with...

CAS 143-67-9 Vinblastine Sulfate

Vinblastine Sulfate
(CAS: 143-67-9)

Vinblastine sulfate, also called cellblastin, derived from C. roseus, as a microtubule disrupter and antineoplastic agent, it binds tubulin and disrupts microtu...

CAS 117048-59-6 Combretastatin A4

Combretastatin A4
(CAS: 117048-59-6)

Combretastatin A4, under the IUPAC name 2-methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenol, inhibits tubulin polymerization (IC50= 2.2 μM). It has demons...

CAS 148408-66-6 Docetaxel Trihydrate

Docetaxel Trihydrate
(CAS: 148408-66-6)

Docetaxel is a cytotoxic agent, which is related to its ability to promote the formation of microtubule bundles and induce sustained mitotic arrest, followed by...

CAS 912-60-7 Noscapine hydrochloride

Noscapine hydrochloride
(CAS: 912-60-7)

Noscapine hydrochloride, the hydrochloride salt form of Noscapine which binds to tubulin and arrests mammalian cells in mitosis at a concentration of 20 µM . No...

CAS 474645-27-7 MMAE

MMAE
(CAS: 474645-27-7)

MMAE, whose full name is Monomethyl auristatin E, inhibits tubulin polymerization so that it inhibits cell division.

CAS 139504-50-0 Mertansine

Mertansine
(CAS: 139504-50-0)

Mertansine, the cytotoxic component in antibody-drug conjugates, attached to a monoclonal antibody through reaction of the thiol group with the SPP (N-succinimi...

CAS 613-11-6 TRx 0237

TRx 0237
(CAS: 613-11-6)

TRx 0237, also called LMT-X or Methylene Blue, is a second-generation tau protein aggregation inhibitor currently in development for the treatment of Alzheimer'...

CAS 141430-65-1 ABT 751

ABT 751
(CAS: 141430-65-1)

ABT 751, also called E7010, is a a novel bioavailable tubulin-binding and antimitotic agent (in neuroblastoma: IC50= 0.6–2.6 μM; in non-neuroblastoma cell line...

CAS 71486-22-1 Vinorelbine

Vinorelbine
(CAS: 71486-22-1)

Vinorelbine, also called Navelbine, a 5′NOR semisynthetic vinca alkaloid which arrests tumor cell growth in metaphase by binding to tubulin and preventing form...

ACI-35

ACI-35 is a liposome-based vaccine designed to stimulate a patient’s immune system to produce antibodies against the misfolded and phosphorylated pathogenic for...

CAS 729605-21-4 XRP44X

XRP44X
(CAS: 729605-21-4)

XRP44X, under the IUPAC name [4-(3-chlorophenyl)piperazin-1-yl]-(5-methyl-2-phenylpyrazol-3-yl)methanone, as an inhibitor of Tubulin it indirectly inhibits Net ...

CAS 714272-27-2 Plinabulin

Plinabulin
(CAS: 714272-27-2)

Plinabulin is a vascular disrupting agent (VDA) against tubulin-depolymerizing with IC50 value of 9.8~18 nM in tumor cells under the development of Nereus Pharm...

CAS 14255-87-9 Parbendazole

Parbendazole
(CAS: 14255-87-9)

Parbendazole, a benzimidazole carbamat used as an antinematodal agent, is a potent inhibitor of microtubule assembly and functions.

CAS 313367-92-9 UA 62784

UA 62784
(CAS: 313367-92-9)

UA 62784, under the IUPAC name 4-[5-(4-methoxyphenyl)-1,3-oxazol-2-yl]fluoren-9-one, a cytotoxic microtubule inhibitor in vitro, causes reversible cell cycle ar...

CAS 108852-90-0 Nemorubicin

Nemorubicin
(CAS: 108852-90-0)

Nemorubicin, currently being developed by Nerviano, is a doxorubicin derivative that differs significantly from its parent drug in terms of spectrum of antitumo...

Chemical Structure

CAS 117048-59-6 Combretastatin A4

Quick Inquiry

Verification code

Featured Items